Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
EMEA recommends new warnings and contraindications for rosiglitazone
Notice type:
Advisory
Date:
24/01/2008
Product name or type:
Avandia, Avandamet & Avaglim
Active Substance:
Rosiglitazone
Problem Or Issue:
The European Medicines Agency (EMEA) has recommended updating the product information for rosiglitazone-containing antidiabetic medicines. Rosiglitazone is available in the European Union as Avandia (rosiglitazone maleate), Avandamet (rosiglitazone maleate/metformin) and Avaglim (rosiglitazone maleate/glimepiride).
Background Information Or Related Documents:
EMEA recommends new warnings and contraindications for rosiglitazone Document
Further Information:
For further information,
click here to read the
Press Release
« Back
Date Printed: 22/09/2023